Malaria

WHO informal consultation with manufacturers of artemisinin-based pharmaceutical products in use for the treatment of malaria

November 2007

Share

Authors:
World Health Organization

Publication details

Number of pages: 33
Publication date: 2007
Languages: English

Downloads


Overview

The presence of oral artemisinin monotherapies in the market continues to represent a threat to the useful therapeutic life of these medicines, by encouraging the development of resistance.

At the meeting, held in Geneva, Switzerland on 24 August 2007, seven new companies declared their willingness to stop marketing artemisinin monotherapies over a short period, increasing to 61.2% (41 out of 67) the proportion of companies willing to comply with WHO recommendations.